In clinical settings, low levels of adropin have been found in individuals with arterial hypertension, obesity, T2DM, metabolic syndrome, coronary artery disease, atherosclerosis, stroke, acute coronary syndrome, chronic kidney disease, and all phenotypes of symptomatic HF [21,22,23,24,25,26,27]. This evidence concerns the gene ENHO and type 2 diabetes mellitus.